The investigators' central hypothesis is that early combination therapy with two PAH-specific oral therapies that have been shown to be well tolerated in the pediatric population, sildenafil and bosentan, will result in better World Health Organization (WHO) functional class at 12 months after initiation of PAH treatment than therapy with sildenafil alone.
Pediatric Pulmonary Hypertension
The investigators' central hypothesis is that early combination therapy with two PAH-specific oral therapies that have been shown to be well tolerated in the pediatric population, sildenafil and bosentan, will result in better World Health Organization (WHO) functional class at 12 months after initiation of PAH treatment than therapy with sildenafil alone.
Mono vs. Dual Therapy for Pediatric Pulmonary Arterial Hypertension
-
The Regents of the University of California, San Francisco, San Francisco, California, United States, 94158
Children's Hospital Colorado, Aurora, Colorado, United States, 80045
Johns Hopkins All Children's Hospital, Saint Petersburg, Florida, United States, 33701
Johns Hopkins Medical Institutions, Baltimore, Maryland, United States, 21287
Boston Children's Hospital, Boston, Massachusetts, United States, 02115
Columbia University Medical Center, New York, New York, United States, 10032
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States, 45229
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States, 19104
Vanderbilt University Medical Center, Nashville, Tennessee, United States, 37232
Baylor College of Medicine, Houston, Texas, United States, 77030
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
3 Months to 18 Years
ALL
No
Johns Hopkins University,
Lewis Romer, MD, PRINCIPAL_INVESTIGATOR, Johns Hopkins University
2026-09-30